Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...

The execs at Haleon, a huge multinational consumer products company, ought to take a good look in the mirror. That is, unless misleading, sleazy marketing is in their mission statement. In that case, ...

That brand is more than just a logo - it’s your company’s ... of consumer marketing can be brought into the B2B pharmaceutical world. If GSK were to make a John Lewis-esque Christmas ad ...

The list extends into the pharma industry, including Pfizer, GSK, and Novo Nordisk. On 14 November, Eli Lilly became a part of this group, after an account using its name and logo sent out a Tweet ...

The weight-loss drug is on track to log over $13 billion in global sales in 2025, according to Evaluate, a pharmaceutical intelligence ... from a Chinese company. GSK acquired Aiolos months ...

With Forbion and General Atlantic leading a round that also involved RA Capital Management, Orbimed, Logos Capital ... focused company was scooped up by GSK just 77 days after launching.

Bearish flow noted in GSK (GSK) Pharma with 1,131 puts trading, or 2x expected. Most active are Mar-25 33 puts and Jan-26 35 puts, with total volume in those strikes near 730 contracts. The Put/Call ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Bearish flow noted in GSK (GSK) Pharma with 1,694 puts trading, or 4x expected. Most active are 2/7 weekly 34 puts and Jan-27 28 puts, with total volume in those strikes near 1,600 contracts.

GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...

GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...